In conclusion, therefore, even if recent findings support the notion of heterozygous PARK2/PARK6 variants representing a strong risk factor for Parkinson’s disease [59], whether or not these heterozygotes with subclinical dysfunction will develop clinical parkinsonism over time is difficult to predict. The gene discussed is PINK1; the disease is Parkinsonism.